glp 1 podcast GLP-1 Drugs - One Thing They Don't Reduce [Podcast] My Life On GLP-1: Series

Madsbad S (2016): Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists

Collectively, these studies reveal that nutrient precursors, gut microbiota, and host participants along the meta-organismal pathway elucidated may serve as new targets for the prevention and treatment of CVD

Retatrutide's Phase 3 trials (the TRIUMPH program) are still ongoing, and direct head-to-head data between the two drugs does not yet exist

It works by: Enhancing insulin secretion in a glucose-dependent manner, which helps lower blood sugar without causing hypoglycemia when used alone Suppressing glucagon release from the pancreas, reducing hepatic glucose production Slowing gastric emptying , which prolongs satiety and reduces appetite Acting on central appetite centers in the hypothalamus to decrease food intake Semaglutide is administered subcutaneously (Ozempic, Wegovy) or orally (Rybelsus) and is primarily eliminated via proteolytic degradation, not through hepatic cytochrome P450 enzymes